Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer: Time To Face The Lyrica Pain

Executive Summary

Pfizer forecast flat US drug prices in 2019 and downplayed large M&A as a way to assuage near-term growth concerns, while investors brace for a challenging period cycling through the loss of Lyrica.


Related Content

Going Generic: Big Brands Poised To Lose Marketing Exclusivity In The US In 2019
Mortality Signal For Pfizer's Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class
BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says
Affinivax’s MAPS Vaccine Technology Reaches Clinic In Under Five Years
Industry's Drug Pricing Power Is Running On Fumes
Lilly Sees New Product Gains, But Older Drugs Still Limit Growth Potential
US Drug Pricing: What A Difference A Year Makes
The Inevitable Is Coming: Price Increases, Starting With Pfizer
Pfizer Has Tafamidis Data In Hand, But Market Development Still A Challenge


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts